Reasons that prevent the inclusion of Alzheimer's disease patients in clinical trials
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Aim: To assess reasons that prevent A lzheimer's disease (AD) patients from being included in clinical trials. Methods: In 2009, we reviewed the L ille M emory C linic's case database to identify patients suitable for inclusion in four AD clinical trials. An initial selection was made on the basis of four criteria: (i) a diagnosis of AD (with or without white matter lesions [WML]), (ii) age, (iii) mini mental state examination (MMSE) score and (iv) symptomatic treatment of AD (cholinesterase inhibitors/memantine). Next, data on patients fulfilling these criteria were reviewed against all the inclusion/exclusion criteria for four clinical trials performed in 2009 at the M emory C linic. Reasons for non‐inclusion were analyzed. Results: Two hundred and five patients were selected according to the four initial criteria. Reasons for subsequently not including some of patients in clinical trials were abnormalities on MRI (56.9%, 88.9% of which were WML), unauthorized medication (37.3%), the lack of a study partner/informant (37.1%), the presence of a non‐authorized disease (24.4%), contraindication to MRI (9%), a change in diagnosis over time (3.9%), visual/auditory impairments (2.9%), alcohol abuse (2%) and an insufficient educational level (1%). Conclusion: A high proportion of AD patients presented with vascular abnormalities on MRI. This was not unexpected, since the patients were selected from the database and, as shown in epidemiologic studies, cerebrovascular diseases are frequently associated with AD. The presence of a study partner is essential for enabling a patient to participate in clinical trials because of the need to record reliably primary and secondary outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MULTI-INFARCT DEMENTIA A CAUSE OF MENTAL DETERIORATION IN THE ELDERLY
HACHINSKI, V (1974) · The Lancet · doi:10.1016/s0140-6736(74)91496-2 · Cited by 1,093
Barriers to Participation in Randomised Controlled Trials
Ross, S., Grant, A., Counsell, C., Gillespie, W., Russell, I., & Prescott, R. (1999) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00141-9 · Cited by 907
Treatment of vascular risk factors is associated with slower decline in Alzheimer disease
Deschaintre, Y., Richard, F., Leys, D., & Pasquier, F. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b59bf3 · Cited by 232
Self-citation
Cited by
Duara, R., & Barker, W. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01185-z · Cited by 187
Walker, V. M., Kehoe, P. G., Martin, R. M., & Davies, N. M. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyz155 · Cited by 96
Walker, V. M., Kehoe, P. G., Martin, R. M., & Davies, N. M. (2018) · doi:10.1101/486878 · Cited by 96
Indorewalla, K. K., O’Connor, M. K., Budson, A. E., Guess (DiTerlizzi), C., & Jackson, J. (2021) · Journal of Alzheimer’s Disease · doi:10.3233/jad-201081 · Cited by 93
“The abovementioned statistic is also especially concerning in light of the evidence that CVD is frequently associated with AD [47, 51] and a significant proportion of AD patients present with vascular abnormalities [47].”
BackgroundAshford, M. T., Raman, R., Miller, G., Donohue, M. C., Okonkwo, O. C., Mindt, M. R., Nosheny, R. L., Coker, G. A., Petersen, R. C., Aisen, P. S., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12640 · Cited by 51
Metadata
- Authors
- Rollin‐Sillaire, A., Breuilh, L., Salleron, J., Bombois, S., Cassagnaud, P., Deramecourt, V., Mackowiak, M., & Pasquier, F.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2013-03-15
- Volume
- 75
- Issue
- 4
- Pages
- 1089-1097
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2099546638
- Cited by
- 28
- References
- 3
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reasons that prevent the inclusion of Alzheimer's disease patients in clinical trials. https://app.cochat.ai/papers/10.1111/j.1365-2125.2012.04423.x
- The paper
- Rollin‐Sillaire, A., Breuilh, L., Salleron, J., Bombois, S., Cassagnaud, P., Deramecourt, V., Mackowiak, M., & Pasquier, F. (2013). Reasons that prevent the inclusion of Alzheimer's disease patients in clinical trials. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2012.04423.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.